Alexander T. Pearson
Papers
5
Total Citations
95
H-Index
4
About
Alexander T. Pearson is a leading clinical researcher in head and neck oncology, whose work centers on transforming treatment for human papillomavirus-associated oropharyngeal cancer (HPV+ OPC). His major contributions lie in pioneering response-adaptive, de-escalation strategies that integrate neoadjuvant immunotherapy and chemotherapy to reduce treatment toxicity without compromising survival. Pearson’s landmark OPTIMA II trial (2021, 30 citations) established the feasibility of risk-based de-escalated locoregional therapy after nivolumab, nab-paclitaxel, and carboplatin. He further advanced this paradigm with the TARGET-HPV trial (2024, 12 citations), testing neoadjuvant HPV16-specific arenavirus-based immunotherapy, and a 2024 study on neoadjuvant nivolumab plus chemotherapy (45 citations) that defined response-adaptive approaches for HPV+ OPC. His research also explores circulating tumor HPV DNA as a dynamic biomarker for treatment selection (2025, 7 citations), and a pooled analysis (2025) confirms favorable functional and survival outcomes with de-escalation. With a cumulative citation impact exceeding 95, Pearson is reshaping curative therapy for HPV-driven head and neck cancers, aiming to preserve quality of life while maintaining excellent oncologic control.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5